$86.1 Million

Vera Therapeutics, Inc.

Follow-on Offering

Bookrunner, February 2022

Vera Therapeutics (the “Company” or “Vera”)  is a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The Company’s lead product candidate, atacicept, a self-administered fusion protein that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), is currently being evaluated for the treatment of immunoglobulin A nephropathy (IgAN).